View Older Stories View More Recent Stories
-
MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
-
Form SC 13G SOLENO THERAPEUTICS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Jnana Therapeutics to Participate in Upcoming Investor Conferences
-
SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
-
Orchard Therapeutics (ORTX) Acquired by Kyowa Kirin for $16/sh Cash plus $1 CVR
-
MBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
-
SAB Biotherapeutics (SABS) Announces Private Placement of up to $130 Million
-
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
-
Form SC 13G CHIMERIX INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
T-knife Therapeutics Announces Four Presentations at the Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
Form SC 13D/A ARS Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Adela Announces $48 Million in Financing and Leadership Addition to Advance Tissue-Agnostic Minimal Residual Disease (MRD) Monitoring Product Portfolio Based on Genome-Wide Methylome Approach
-
Form SC 13G CymaBay Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Cytek Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Hyku Biosciences Launches With $56M to Advance its Covalent Medicines Platform to Expand the Boundaries of Drug Discovery
-
EntityRisk Launches PROVEN™ Platform
-
MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults
-
Mariana Oncology Announces $175 Million Series B Financing
-
Jnana Therapeutics to Participate in Upcoming Investor Conferences
-
Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines
-
Star Therapeutics Raises $90 Million Financing to Accelerate Its Pipeline of Novel Antibody Therapies and Growth of Its Portfolio Companies
-
Sortera Technologies Attends IAA Mobility 2023 Conference in Munich
-
Form SC 13D ARS Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Jnana Therapeutics Presents Additional Data from Phase 1a Clinical Study of JNT-517 at SSIEM Annual Symposium
-
Sortera Technologies Closes $30.5 Million in New Funding to Fully Commercialize Its State-of-the-Art Upcycling Facility
-
Inhibrx Inc. (INBX) Announces $200M Financing at $19.35/sh
-
Inhibrx Announces $200 Million Private Placement Financing
-
MBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference
-
Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics
-
Form SC 13G Taysha Gene Therapies, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
ExcepGen Emerges From Stealth with New Funding for its Nucleic Acid Therapeutics Platform
-
Form SC 13G Gracell Biotechnologies Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G NEKTAR THERAPEUTICS Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline
-
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
-
Form SC 13G/A BELLUS Health Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Kinnate Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
-
Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
-
Taysha Gene Therapies (TSHA) Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial
-
Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results
-
Taysha Gene Therapies (TSHA) Announces $150M Financing
-
Taysha Gene Therapies Announces $150 Million Private Placement Financing
-
Form SC 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A DICE Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Jnana Therapeutics Announces Dosing of First Participant in Phase 1b Clinical Trial of JNT-517 in Individuals with PKU
-
MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
-
Gracell Biotechnologies (GRCL) Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
-
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors

